Research programme: Eph-targeting peptides - MedImmune/Burnham Institute
Latest Information Update: 22 Jan 2008
At a glance
- Originator The Burnham Institute
- Mechanism of Action Protein tyrosine kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Jun 2007 MedImmune has been acquired by AstraZeneca
- 08 Dec 2005 Preclinical trials in Cancer in USA (unspecified route)